Treatment of diabetes mellitus in patients with chronic hepatitis B: Are SGLT2 inhibitors hitting the sweet spot?

Article Medicine, General & Internal

Time-trends in disease characteristics and comorbidities in patients with chronic hepatitis B in the period 1980-2020

D. P. C. van der Spek et al.

Summary: The characteristics of newly referred chronic hepatitis B (CHB) patients are changing, with older age, less active HBV-related liver disease, and a higher likelihood of being co-affected by metabolic dysfunction associated fatty liver disease (MAFLD). These findings provide guidance for resource allocation to address the changing characteristics of the CHB population.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2023)

Add to Collection

Article Gastroenterology & Hepatology

Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes

Lung-Yi Mak et al.

Summary: This study found that high glycemic burden was associated with the development of hepatocellular carcinoma (HCC) and fibrosis progression among patients with chronic hepatitis B and type 2 diabetes. The findings highlight the importance of glycemic control in reducing liver-related complications.

HEPATOLOGY (2023)

Add to Collection

Review Pharmacology & Pharmacy

Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials

Rosaria Benedetti et al.

Summary: Diabetic patients have an increased cancer risk and higher mortality rate. High blood glucose plays a role in promoting cancer progression. Inflammation is a common feature in both diabetes and cancer patients, and the correlation between high blood glucose and inflammation makes tumor development more susceptible. Glycemic control is crucial in treating diabetes and also has favorable outcomes in cancer.

PHARMACOLOGICAL RESEARCH (2022)

Add to Collection

Review Pharmacology & Pharmacy

The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications

Konstantinos Arvanitakis et al.

Summary: SGLT2 inhibitors may have the potential to modulate hallmarks of HCC, but further research is needed to evaluate the risk-to-benefit ratio, combination with other drugs, and safety aspects.

PHARMACOLOGICAL RESEARCH (2022)

Add to Collection

Article Endocrinology & Metabolism

Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Haleh Chehrehgosha et al.

Summary: This study demonstrated that treatment with empagliflozin for 24 weeks led to significant improvement in liver steatosis and fibrosis compared to placebo in patients with NAFLD and T2DM. Additionally, empagliflozin treatment resulted in reductions in body weight and abdominal fat area.

DIABETES THERAPY (2021)

Add to Collection

Article Medicine, General & Internal

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Philip N. Newsome et al.

Summary: This phase 2 trial demonstrated that treatment with semaglutide resulted in a significantly higher percentage of patients with NASH resolution compared to placebo in patients with NASH, but did not show a significant between-group difference in the percentage of patients with an improvement in fibrosis stage.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Gastroenterology & Hepatology

Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B

Laurens A. van Kleef et al.

Summary: The study found that the presence of metabolic dysfunction-associated fatty liver disease (MAFLD) in patients with chronic hepatitis B (CHB) is associated with an increased risk of liver-related adverse events and death. Among patients with MAFLD, the presence of steatohepatitis did not increase the risk of adverse outcomes.

JHEP REPORTS (2021)

Add to Collection

Article Medicine, Research & Experimental

Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

Hoda Taheri et al.

ADVANCES IN THERAPY (2020)

Add to Collection

Treatment of diabetes mellitus in patients with chronic hepatitis B: Are SGLT2 inhibitors hitting the sweet spot?

Related references

Export Citation

Share Paper